IRIS
SPAGNUOLO, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.144
NA - Nord America 3.718
AS - Asia 3.367
SA - Sud America 736
Continente sconosciuto - Info sul continente non disponibili 269
AF - Africa 68
OC - Oceania 6
Totale 12.308
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.488
RU - Federazione Russa 2.261
SG - Singapore 1.130
CN - Cina 1.087
IT - Italia 596
BR - Brasile 594
HK - Hong Kong 346
RO - Romania 344
VN - Vietnam 322
SE - Svezia 259
DE - Germania 174
FR - Francia 152
BD - Bangladesh 139
GB - Regno Unito 116
CA - Canada 110
IN - India 83
AR - Argentina 59
FI - Finlandia 54
MX - Messico 43
ID - Indonesia 41
IQ - Iraq 39
AT - Austria 34
PL - Polonia 30
TR - Turchia 28
ES - Italia 27
ZA - Sudafrica 27
JP - Giappone 26
NL - Olanda 25
EC - Ecuador 23
CO - Colombia 19
IE - Irlanda 15
MY - Malesia 15
PK - Pakistan 15
JM - Giamaica 14
PH - Filippine 13
HN - Honduras 12
SA - Arabia Saudita 12
UZ - Uzbekistan 12
AE - Emirati Arabi Uniti 11
LT - Lituania 10
NP - Nepal 10
TN - Tunisia 10
VE - Venezuela 10
CR - Costa Rica 9
CL - Cile 8
GT - Guatemala 8
NI - Nicaragua 8
PY - Paraguay 8
UA - Ucraina 8
CZ - Repubblica Ceca 7
DO - Repubblica Dominicana 6
KE - Kenya 6
MA - Marocco 6
PE - Perù 6
UY - Uruguay 6
AU - Australia 5
BE - Belgio 5
EE - Estonia 5
OM - Oman 5
PT - Portogallo 5
SV - El Salvador 5
AZ - Azerbaigian 4
BB - Barbados 4
DZ - Algeria 4
IL - Israele 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
CH - Svizzera 3
CI - Costa d'Avorio 3
NG - Nigeria 3
TH - Thailandia 3
EU - Europa 2
GE - Georgia 2
IR - Iran 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
KZ - Kazakistan 2
LV - Lettonia 2
MD - Moldavia 2
NO - Norvegia 2
PA - Panama 2
PS - Palestinian Territory 2
RS - Serbia 2
SC - Seychelles 2
UG - Uganda 2
AL - Albania 1
BG - Bulgaria 1
BM - Bermuda 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
ET - Etiopia 1
GA - Gabon 1
GP - Guadalupe 1
GY - Guiana 1
HR - Croazia 1
JO - Giordania 1
Totale 12.030
Salva come PNG Salva come JPEG
Città #
Singapore 558
Ashburn 512
Moscow 455
San Jose 427
Dallas 345
Hong Kong 342
Milan 184
New York 184
Council Bluffs 180
Shanghai 165
Beijing 156
Hefei 140
Lauterbourg 121
Ho Chi Minh City 109
Princeton 97
Lawrence 95
Los Angeles 86
Hanoi 77
Phoenix 69
Santa Clara 68
Munich 55
São Paulo 47
Boardman 44
Nuremberg 42
Orem 41
Denver 38
Helsinki 34
Montreal 32
Rome 32
Warsaw 29
Atlanta 28
London 28
Chennai 27
Miano 26
Tokyo 26
Brooklyn 23
Guangzhou 23
Houston 22
Frankfurt am Main 20
Chicago 19
Da Nang 19
Manchester 19
Toronto 19
Vienna 18
Buffalo 17
Stockholm 17
Baghdad 16
Dublin 16
Mexico City 16
Poplar 15
Seattle 15
Shenzhen 14
Washington 14
Brasília 13
Johannesburg 13
Rio de Janeiro 13
Amsterdam 12
Ankara 12
Charlotte 12
Curitiba 12
Falkenstein 12
Las Vegas 12
Naples 12
Turku 12
Biên Hòa 11
Guayaquil 11
Tashkent 11
Boston 10
Barnet 9
Bologna 9
Haiphong 9
Memphis 9
Mumbai 9
San Francisco 9
Belo Horizonte 8
Kingston 8
Kuala Lumpur 8
Madrid 8
Managua 8
Pietra Ligure 8
Porto Alegre 8
Pune 8
Querétaro 8
Sorocaba 8
Columbus 7
Miami 7
Monza 7
North Bergen 7
Philadelphia 7
San Pedro Sula 7
The Dalles 7
Brescia 6
City of London 6
Goiânia 6
Guatemala City 6
Hải Dương 6
Lappeenranta 6
New Delhi 6
Ottawa 6
Quanzhou 6
Totale 5.636
Salva come PNG Salva come JPEG
Nome #
Monkeypox in a patient with undifferentiated connective tissue disease 260
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 258
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 222
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 211
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 195
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 192
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort 155
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 137
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study 136
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 132
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 132
Cardiac implantable electronic device infections: impact of initiation of antimicrobial treatment before or after device removal on microbiological yield 128
Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience 126
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 124
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 121
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting 121
Achieving virological control in pan-resistant HIV-1 infection: A case series 120
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 120
Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV 120
Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients 115
Combination of High-Dose Daptomycin and Ceftriaxone for Cardiac Implantable Electronic Device Infections: A 10-Year Experience 114
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 113
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors 113
Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals 112
Impact of Respiratory Syncytial Virus (RSV) on adult haematology oncology patients 111
Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach 111
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry 111
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 110
Bictegravir 108
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 108
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 107
Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection 103
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 103
Inflammation burden score in multidrug-resistant HIV-1 infection 102
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 102
Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting 102
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 102
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 101
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens 99
Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy 99
Disseminated Mycobacterium chimaera infection favoring the development of Kaposi’s sarcoma: a case report 98
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data 97
All-Cause Mortality in People With Four-Class Drug-Resistant Human Immunodeficiency Virus: A Matched Cohort Analysis With Data From the PRESTIGIO Registry 95
Should we expect weight changes in people with HIV and a reported weight gain only by switching antiretroviral therapy? 95
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 95
Cardiovascular risk and dyslipidemia among persons living with HIV: A review 95
Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study) 95
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection 95
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium 93
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 93
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 91
Addressing late HIV presentation: the current knowledge and unmet needs 87
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 86
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 86
Non-Hodgkin lymphoma risk in adults living with HIV across five continents 84
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 82
Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance 82
Darunavir for the treatment of HIV infection 81
An evaluation of cabotegravir for HIV treatment and prevention 80
Chronic hepatitis B and C virus infection and risk for non-hodgkin lymphoma in HIV-infected patients: A cohort study 80
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 79
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 78
Is shorter duration of antibiotic treatment feasible in patients with cardiac implantable electronic device infections undergoing device removal? A propensity-adjusted analysis of a 10-year retrospective cohort 78
Cervical cancer risk in women living with HIV across four continents: A multicohort study 77
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 77
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 77
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 77
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 76
Uberti Foppa C, Gaiera G, Nunzi E, Spagnuolo V Capitolo 101 Infezioni sistemiche in: Rugarli Medicina interna sistematica 76
Multidrug-resistant Mycoplasma genitalium urethritis: successful eradication with sequential therapy 73
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 73
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort 73
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration 72
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry 71
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 70
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options—the ICONA Foundation cohort study 68
PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests" 67
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitors 66
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study 66
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. 66
Immune recovery and T cell subset analysis during effective treatment with maraviroc 65
Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study 65
Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 65
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting 65
Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV 65
PRESTIGIO RING: “Persistent low-level viremia with preserved immunological profile in people with multidrug-resistant HIV: is it time to defer switching?” 65
Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. 64
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 64
Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients 64
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 64
Long-term suppression of viral replication in HIV-related lymphoma survivors: a case-control study 63
Impact of analytical treatment interruption on burden and diversification of hiv peripheral reservoir: A pilot study 62
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 61
Changing Incidence and Risk Factors for Kaposi Sarcoma by Time since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies 61
Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies 60
Changes in Darunavir/r Resistance Score After Previous Failure to Tipranavir/r in HIV-1-Infected Multidrug-Resistant Patients 60
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir 60
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply 60
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients 60
Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection 60
Totale 9.759
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.352
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.352
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202278 0 0 0 18 9 9 2 13 7 4 9 7
2022/2023494 206 103 28 4 8 42 43 36 19 2 1 2
2023/2024463 11 18 81 31 49 121 6 43 1 4 27 71
2024/20252.159 194 25 42 64 89 164 661 167 250 132 114 257
2025/20267.296 523 497 480 903 538 243 615 581 1.941 448 280 247
2026/20271.726 256 426 409 635 0 0 0 0 0 0 0 0
Totale 12.308